0000000000531498

AUTHOR

Michael Stadler

showing 3 related works from this author

Changes in Immunosuppressive Treatment of Chronic Graft-versus-Host Disease: Comparison of 2 Surveys within Allogeneic Hematopoietic Stem Cell Transp…

2019

Abstract Chronic graft-versus-host disease (cGVHD) remains the leading cause of late morbidity and mortality. Despite the growing number of treatment options in cGVHD, evidence remains sparse. The German-Austrian-Swiss GVHD Consortium performed a survey on clinical practice in treatment of cGVHD among transplant centers in Germany, Austria, and Switzerland in 2009 and 2018 and compared the results. The survey performed in 2009 contained 20 questions on first-line treatment and related issues and 4 questions on second-line scenarios followed by a survey on all systemic and topic treatment options known and applied, with 31 of 36 transplant centers (86%) responding. The survey in 2018 repeate…

AdultMalemedicine.medical_specialtyRuxolitinibMedizinBronchiolitis obliteransGraft vs Host DiseaseDiseasechemistry.chemical_compoundPiperidinesGermanyNitrilesmedicineHumansIntensive care medicineBronchiolitis ObliteransImmunosuppressive treatmentImmunosuppression TherapyTransplantationbusiness.industryAdenineHematopoietic Stem Cell TransplantationHematologymedicine.diseaseClinical trialGraft-versus-host diseasePyrimidineschemistryIbrutinibAustriaChronic DiseasePyrazolesFemaleAllogeneic hematopoietic stem cell transplantbusinessSwitzerlandmedicine.drugBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
researchProduct

Compassionate Use of Sorafenib in Relapsed and Refractory Flt3-ITD Positive Acute Myeloid Leukemia.

2009

Abstract Abstract 2060 Poster Board II-37 Introduction: The Flt3-internal tandem duplication can be found in up to 30% of all acute myeloid leukemia (AML) patients and confers a poor risk status characterized by an increased relapse rate and poor overall survival. Moreover, Flt3-ITD-positive AML patients relapsing after allogenic stem cell transplantation (SCT) have very limited therapeutic options. Sorafenib is a multikinase inhibitor that is approved for the treatment of metastatic renal cell and hepatocellular carcinoma. Besides targeting Raf, the platelet derived growth factor receptor (PDGFR) and the vascular endothelial growth factor receptor (VEGFR) it has also significant inhibitory…

OncologySorafenibmedicine.medical_specialtyChemotherapybusiness.industrymedicine.medical_treatmentImmunologyInduction chemotherapyMyeloid leukemiaCell BiologyHematologymedicine.diseaseBiochemistryTransplantationmedicine.anatomical_structureTolerabilityhemic and lymphatic diseasesHepatocellular carcinomaInternal medicinemedicineBone marrowbusinessmedicine.drugBlood
researchProduct

Role of Donor Clonal Hematopoiesis in Allogeneic Hematopoietic Stem-Cell Transplantation

2018

Purpose Clonal hematopoiesis of indeterminate potential (CHIP) occurs in the blood of approximately 20% of older persons. CHIP is linked to an increased risk of hematologic malignancies and of all-cause mortality; thus, the eligibility of stem-cell donors with CHIP is questionable. We comprehensively investigated how donor CHIP affects outcome of allogeneic hematopoietic stem-cell transplantation (HSCT). Methods We collected blood samples from 500 healthy, related HSCT donors (age ≥ 55 years) at the time of stem-cell donation for targeted sequencing with a 66-gene panel. The effect of donor CHIP was assessed on recipient outcomes, including graft-versus-host disease (GVHD), cumulative incid…

MaleOncologyCancer Researchmedicine.medical_specialtyMyeloidmedicine.medical_treatmentMedizinGraft vs Host DiseaseHematopoietic stem cell transplantationDiseaseGene FrequencyInternal medicinemedicineHumansTransplantation HomologousCumulative incidenceAgedRetrospective Studiesbusiness.industryClonal hematopoiesisAge FactorsHematopoietic Stem Cell TransplantationMiddle AgedHematopoietic Stem CellsHematopoiesisTransplantationHaematopoiesisTreatment Outcomemedicine.anatomical_structureIncreased riskOncologyHematologic NeoplasmsMutationFemaleUnrelated DonorsbusinessJournal of Clinical Oncology
researchProduct